The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.

PRIORITY PRESS - 53rd Annual Meeting & Exposition of the American Society of Hematology

Simplifying Monitoring with Oral Anticoagulants

San Diego, California / December 10-13, 2011

San Diego - The choice of oral anticoagulants has expanded with the introduction of agents that do not require therapeutic drug monitoring. In new comparative data with warfarin, these agents are continuing to demonstrate advantages in a...

MEDICAL FRONTIERS - Canadian Association of Nephrology Nurses and Technologists (CANNT) 2011

Partnering with Patients on Hemodialysis: Nursing Support, Advocacy and Skills

Calgary, Alberta / October 20-22, 2011

Chief Medical Editor: Dr. Léna Coïc, Montréal, Quebec A major preoccupation for hemodialysis (HD) patients is the many decisions they must make throughout the trajectory of their care. Here at CANNT, HD nurse...

PRIORITY PRESS - XXIII Congress of the International Society on Thrombosis and Haemostasis (ISTH)/ 57th Annual Scientific and Standardization Committee (SSC) Meeting

Advances in the Treatment of Hemophilia B

Kyoto, Japan / July 23-28, 2011

Kyoto - Hemophilia B is the inherited disorder characterized by a deficiency in blood coagulation factor IX (FIX). Current treatment for hemophilia B is plasma-derived FIX or recombinant FIX (rFIX). Although rFIX avoids the risk of viral...

PRIORITY PRESS - 17th Congress of the International Liver Transplantation Society (ILTS)

Simplifying Immunosuppression for Liver Transplant Recipients: A Lifelong Commitment to Optimize Patient and Graft Survival

Valencia, Spain / June 22-25, 2011

Valencia - Following organ transplantation, anti-rejection drug efficacy is critical to optimal patient and graft survival but so, too, are tolerability and ease of administration. The calcineurin inhibitors (CNIs) have a long track record...

PRIORITY PRESS - 16th Congress of the European Hematology Association (EHA)

Improving Response Rates and Duration in Patients with Multiple Myeloma

London, UK / June 9-12, 2011

London - Initially studied in the treatment of multiple myeloma patients in relapsed and refractory settings, proteasome inhibitor-based regimens have now been shown to improve outcomes in transplant-eligible and -ineligible patients with...

MEDICAL FRONTIERS - 16th Congress of the European Hematology Association (EHA)

Improving Responses to First-line Treatment in Chronic Myeloid Leukemia

London, United Kingdom / June 9-12, 2011

London - With the introduction of the first tyrosine kinase inhibitor (TKI) 10 years ago, treatment of chronic myeloid leukemia (CML) was revolutionized. Imatinib became the standard of care and in follow-up analysis of clinical trials it...

PRIORITY PRESS - 13th International Myeloma Workshop

Increasing Response and Reducing Adverse Events: An Exploration of Dosing Schedules and Combination Therapies for Multiple Myeloma

Paris, France / May 3-6, 2011

Paris - Proteasome inhibitor-containing regimens have improved response rates and response duration across all disease stages of multiple myeloma (MM) in transplant-eligible and -ineligible patients. New data presented here at the Myeloma...

PRIORITY PRESS - 52nd Annual Meeting and Exposition of the American Society of Hematology

A First-line Option for Second-generation TKIs in Chronic Myeloid Leukemia

Orlando, Florida / December 4-7, 2010

Orlando - Second-generation tyrosine kinase inhibitors (TKIs) are replacing imatinib as first-line therapy for Philadelphia chromosome-positive chronic myeloid leukemia (CML), according to practice-changing data presented at the ASH...

PRIORITY PRESS - 52nd Annual Meeting and Exposition of the American Society of Hematology

Evaluating Anticancer Effects of Bisphosphonates in Myeloma

Orlando, Florida / December 4-7, 2010

Orlando - Bisphosphonates have demonstrated efficacy for preventing skeletal-related events in multiple myeloma and other cancers. Beyond the beneficial bone effects, evidence had emerged to suggest that nitrogen-containing bisphosphonates...

PAGE 4 OF 9   1 2 3 4 5 6 7 8 9